Literature DB >> 12923398

Selective cyclo-oxygenase-2 inhibition with parecoxib acutely impairs endothelium-dependent vasodilatation in patients with essential hypertension.

Daniel Bulut1, Sina Liaghat, Christoph Hanefeld, Rouven Koll, Thomas Miebach, Andreas Mügge.   

Abstract

BACKGROUND: Cyclo-oxygenase (COX)-2 isoform appears to be a major source of the vasodilator, prostacyclin. Both prostacyclin and nitric oxide may contribute to the regulation of vascular tone and endothelial-mediated homeostasis.
OBJECTIVE: To evaluate the effects of acute COX-2 inhibition on endothelial function in the forearm circulation of patients with essential hypertension.
METHODS: Forty patients with essential hypertension as the only risk factor were studied. Forearm blood flow was measured by venous occlusion phlethysmography. Vascular responses were measured after intra-arterial infusion of the endothelium-dependent agonist acetylcholine (15, 30, or 40 microg/min) and the endothelium-independent agonist nitroprusside (1.6, 3.2, or 4.0 microg/min). Patients were allocated randomly to groups to receive the non-selective COX-inhibitor, acetylsalicylate-lysin (500 mg intravenously), or the selective COX-2 inhibitor, parecoxib, an injectable prodrug of valdecoxib (20 mg intravenously). The infusion procedure was repeated 30 min later.
RESULTS: Acetylcholine increased concentration-dependent forearm blood flow. This increase was significantly augmented by acetylsalicylate-lysin, but significantly diminished by parecoxib. Neither acetylsalicylate-lysin nor parecoxib modified the vasodilator responses to nitroprusside.
CONCLUSION: COX-2 inhibition with the prodrug, parecoxib, diminishes the acetylcholine-induced vasodilatation in the forearm circulation of patients with essential hypertension. It is speculated that the production of vasodilator prostaglandins may be important in pathological states with endothelial dysfunction, at least in patients with essential hypertension.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12923398     DOI: 10.1097/00004872-200309000-00015

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  15 in total

Review 1.  Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?

Authors:  Irmgard Tegeder; Gerd Geisslinger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-04-04       Impact factor: 3.000

2.  Effects of nitric oxide synthase inhibition with or without cyclooxygenase-2 inhibition on resting haemodynamics and responses to exendin-4.

Authors:  S M Gardiner; J E March; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  2006-10-03       Impact factor: 8.739

Review 3.  Human endothelial dysfunction: EDRFs.

Authors:  Andreas J Flammer; Thomas F Lüscher
Journal:  Pflugers Arch       Date:  2010-04-12       Impact factor: 3.657

4.  Sex differences in salt sensitivity to nitric oxide dependent vasodilation in healthy young adults.

Authors:  John H Eisenach; Leah R Gullixson; Susan L Kost; Michael J Joyner; Stephen T Turner; Wayne T Nicholson
Journal:  J Appl Physiol (1985)       Date:  2011-12-22

Review 5.  Endothelium-mediated control of vascular tone: COX-1 and COX-2 products.

Authors:  Michel Félétou; Yu Huang; Paul M Vanhoutte
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

6.  Cyclo-oxygenase-2 inhibition and endothelium-dependent vasodilation in younger vs. older healthy adults.

Authors:  John H Eisenach; Leah R Gullixson; Alexander R Allen; Susan L Kost; Wayne T Nicholson
Journal:  Br J Clin Pharmacol       Date:  2014-10       Impact factor: 4.335

Review 7.  Valdecoxib: a review of its use in the management of osteoarthritis, rheumatoid arthritis, dysmenorrhoea and acute pain.

Authors:  Caroline Fenton; Gillian M Keating; Antona J Wagstaff
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Globotriaosylsphingosine accumulation and not alpha-galactosidase-A deficiency causes endothelial dysfunction in Fabry disease.

Authors:  Mehdi Namdar; Catherine Gebhard; Rafael Studiger; Yi Shi; Pavani Mocharla; Christian Schmied; Pedro Brugada; Thomas F Lüscher; Giovanni G Camici
Journal:  PLoS One       Date:  2012-04-30       Impact factor: 3.240

9.  Deletion of Protein Tyrosine Phosphatase 1B (PTP1B) Enhances Endothelial Cyclooxygenase 2 Expression and Protects Mice from Type 1 Diabetes-Induced Endothelial Dysfunction.

Authors:  David J Herren; David J Herre; J Blake Norman; Ruchi Anderson; Michel L Tremblay; Anne-Cecile Huby; Eric J Belin de Chantemèle
Journal:  PLoS One       Date:  2015-05-14       Impact factor: 3.240

Review 10.  Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritis.

Authors:  Isla S Mackenzie; Daniel Rutherford; Thomas M MacDonald
Journal:  Arthritis Res Ther       Date:  2008-10-17       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.